Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.
Go back to Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.| Regeneron (NASDAQ: REGN) | Delayed: 612.50 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $612.50 | 52 Week High | $592.36 | |||
| Open | $612.50 | 52 Week Low | $325.35 | |||
| Day High | $612.50 | P/E | 160.76 | |||
| Day Low | $612.50 | EPS | $3.81 | |||
| Volume | 3,456 | |||||
| Regeneron (NASDAQ: REGN) | Delayed: 612.50 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $612.50 | 52 Week High | $592.36 | |||
| Open | $612.50 | 52 Week Low | $325.35 | |||
| Day High | $612.50 | P/E | 160.76 | |||
| Day Low | $612.50 | EPS | $3.81 | |||
| Volume | 3,456 | |||||
